病例报告：4岁男孩肾上腺皮质癌大剂量米托坦辅助治疗
Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy.
作者信息
Goto Takako, Miyako Kenichi, Kuromaru Ryuichi, Ihara Kenji, Torisu Hiroyuki, Sanefuji Masafumi, Nagamatsu Rie, Hara Toshiro
机构信息
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; Present: Department of Pediatrics, Beppu Medical Center, Beppu, Japan.
出版信息
Clin Pediatr Endocrinol. 2008;17(3):71-4. doi: 10.1297/cpe.17.71. Epub 2008 Aug 8.
Abstract
This report concerns control of adrenocortical carcinoma in a 4-yr-old boy by adjuvant mitotane therapy. He presented precocious puberty and was diagnosed with adrenocortical carcinoma. He underwent surgical resection, and adjuvant mitotane therapy was initiated, leading to a final dose of 5.0 g/day. Despite monitoring of the plasma mitotane level, encephalopathy developed 5 mo after initiation. Although he recovered from the encephalopathy, careful follow-up of his growth and development is necessary. On the other hand, he has been free of recurrence and metastases for 3 yr since discontinuation of mitotane. A high dose of mitotane is potentially effective as an adjuvant chemotherapy for adrenocortical carcinoma, although optimal and safe usage needs to be established for children.
摘要
本报告涉及一名4岁男孩通过米托坦辅助治疗控制肾上腺皮质癌的情况。他出现性早熟，被诊断为肾上腺皮质癌。他接受了手术切除，并开始进行米托坦辅助治疗，最终剂量达到5.0克/天。尽管监测了血浆米托坦水平，但在开始治疗5个月后出现了脑病。虽然他从脑病中康复，但仍有必要对其生长发育进行密切随访。另一方面，自停用米托坦以来，他已3年无复发和转移。高剂量米托坦作为肾上腺皮质癌的辅助化疗可能有效，尽管需要为儿童确定最佳和安全的用法。
相似文献
1
Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy.病例报告：4岁男孩肾上腺皮质癌大剂量米托坦辅助治疗
Clin Pediatr Endocrinol. 2008;17(3):71-4. doi: 10.1297/cpe.17.71. Epub 2008 Aug 8.
2
Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.低剂量米托坦诱发一名5岁肾上腺皮质癌女童出现神经和内分泌并发症。
Ann Pediatr Endocrinol Metab. 2022 Sep;27(3):236-241. doi: 10.6065/apem.2142044.022. Epub 2021 Oct 18.
3
Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma.低剂量米托坦作为肾上腺皮质癌辅助化疗引起的显著短暂性高胆固醇血症。
J Atheroscler Thromb. 2014;21(12):1326-9. doi: 10.5551/jat.27557. Epub 2014 Nov 12.
4
Local advanced adrenocortical cancer with a long-term recurrence-free survival treated with complete surgical excision and adjuvant therapy with a very low-dose mitotane.经手术完整切除并采用极低剂量米托坦辅助治疗后长期无复发生存的局部晚期肾上腺皮质癌
IJU Case Rep. 2020 Jul 15;3(6):233-235. doi: 10.1002/iju5.12196. eCollection 2020 Nov.
5
Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor.米托坦治疗儿童肾上腺皮质癌：一种强效内分泌干扰物。
Endocrinol Diabetes Metab Case Rep. 2018 Aug 23;2018. doi: 10.1530/EDM-18-0059. eCollection 2018.
6
LONG-TERM FOLLOW UP AND TREATMENT OUTCOMES OF A 2 YEAR-OLD-BOY WITH METASTATIC TESTOSTERONE-SECRETING ADRENOCORTICAL CARCINOMA.一名2岁分泌睾酮的转移性肾上腺皮质癌男童的长期随访及治疗结果
AACE Clin Case Rep. 2020 Aug 6;6(6):e300-e304. doi: 10.4158/ACCR-2020-0354. eCollection 2020 Nov-Dec.
7
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.肾上腺皮质癌辅助米托坦治疗的最佳疗程是多久？一个未解决的问题。
J Pers Med. 2021 Apr 4;11(4):269. doi: 10.3390/jpm11040269.
8
Adjuvant mitotane treatment for adrenocortical carcinoma.米托坦辅助治疗肾上腺皮质癌。
N Engl J Med. 2007 Jun 7;356(23):2372-80. doi: 10.1056/NEJMoa063360.
9
Adjunctive treatment of adrenocortical carcinoma.肾上腺皮质癌的辅助治疗
Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):221-6. doi: 10.1097/MED.0b013e3282fdf4c0.
10
Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report.肾上腺外、无功能性肾上腺皮质癌表现为急性腹痛：一例报告。
J Med Case Rep. 2020 Jul 8;14(1):107. doi: 10.1186/s13256-020-02408-7.
引用本文的文献
1
Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy.使用基于基因共表达网络的药物重新定位策略，肾上腺皮质癌生存基因HMMR被确定为氟尿嘧啶和表柔比星的作用靶点。
Sci Rep. 2025 Jul 17;15(1):25912. doi: 10.1038/s41598-025-10452-w.
2
Nutritional support in children treated for advanced adrenocortical carcinoma.晚期肾上腺皮质癌患儿的营养支持
Pediatr Surg Int. 2025 Jan 23;41(1):71. doi: 10.1007/s00383-025-05974-3.
3
Adrenal cortical carcinoma: Paediatric aspects - literature review.肾上腺皮质癌：儿科方面——文献综述。
Pediatr Endocrinol Diabetes Metab. 2024;30(2):81-90. doi: 10.5114/pedm.2024.139271.
4
Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma - case series and literature review.儿童肾上腺皮质癌应用米托坦治疗期间出现性早熟和其他内分泌紊乱 - 病例系列及文献复习。
Pediatr Endocrinol Diabetes Metab. 2024;30(1):14-28. doi: 10.5114/pedm.2023.133315.
5
Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.米托坦治疗肾上腺皮质癌的神经学不良事件：一项初步研究的结果
Front Oncol. 2023 Aug 14;13:1222002. doi: 10.3389/fonc.2023.1222002. eCollection 2023.
6
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.儿童使用依托咪酯-米托坦：可逆性副作用和神经毒性的可靠证据
Discov Oncol. 2022 Apr 18;13(1):25. doi: 10.1007/s12672-022-00486-1.
7
Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.低剂量米托坦诱发一名5岁肾上腺皮质癌女童出现神经和内分泌并发症。
Ann Pediatr Endocrinol Metab. 2022 Sep;27(3):236-241. doi: 10.6065/apem.2142044.022. Epub 2021 Oct 18.
8
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.米托坦的挑战性药代动力学：一种需要新包装的老药。
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21.
9
Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.米托坦在肾上腺皮质癌中的作用——综述与现状
Eur Endocrinol. 2018 Sep;14(2):62-66. doi: 10.17925/EE.2018.14.2.62. Epub 2018 Sep 10.
10
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.大剂量米托坦诱发的脑病在肾上腺皮质癌治疗中的应用
Oncologist. 2018 Mar;23(3):389-390. doi: 10.1634/theoncologist.2017-0426. Epub 2017 Nov 30.
本文引用的文献
1
Virilizing Adrenocortical Carcinoma Invading the Right Atrium with Histological High-Grade Malignancy and p53 Mutation in a 3-Year-Old Child: Indication of Post Operative Adjuvant Chemotherapy.一名3岁儿童患具有组织学高级别恶性和p53突变的侵袭性右心房的男性化肾上腺皮质癌：术后辅助化疗指征
Clin Pediatr Endocrinol. 2004;13(1):25-32. doi: 10.1297/cpe.13.25. Epub 2004 Jul 7.
2
Adjuvant mitotane treatment for adrenocortical carcinoma.米托坦辅助治疗肾上腺皮质癌。
N Engl J Med. 2007 Jun 7;356(23):2372-80. doi: 10.1056/NEJMoa063360.
3
Multiple primary cancers in patients with osteosarcoma: influence of anticancer drugs and genetic factors.骨肉瘤患者的多原发性癌症：抗癌药物和遗传因素的影响
Am J Clin Oncol. 2004 Jun;27(3):220-4. doi: 10.1097/01.coc.0000054534.43117.76.
4
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.肾上腺皮质肿瘤患儿的临床及预后特征：来自国际儿科肾上腺皮质肿瘤登记处的报告
J Clin Oncol. 2004 Mar 1;22(5):838-45. doi: 10.1200/JCO.2004.08.085.
5
Studies of the pharmacology of o,p'DDD in man.人用邻对滴滴滴的药理学研究。
J Lab Clin Med. 1961 Aug;58:296-304.
6
Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.一名患有转移性肾上腺皮质癌婴儿的长期（15年）预后情况。
J Clin Endocrinol Metab. 2002 Oct;87(10):4452-6. doi: 10.1210/jc.2001-011978.
7
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.监测血浆1,1-二氯二苯二氯乙烷（邻，对-DDD）水平对肾上腺皮质癌患者治疗的影响。
Cancer. 2001 Sep 15;92(6):1385-92. doi: 10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2.
8
Adrenocortical tumors in children.儿童肾上腺皮质肿瘤
J Pediatr Surg. 2001 Apr;36(4):549-54. doi: 10.1053/jpsu.2001.22280.
9
Clinical and prognostic aspects of adrenocortical neoplasms in childhood.儿童肾上腺皮质肿瘤的临床及预后特征
Med Pediatr Oncol. 1999 Feb;32(2):106-11. doi: 10.1002/(sici)1096-911x(199902)32:2<106::aid-mpo7>3.0.co;2-j.
10
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.米托坦治疗肾上腺皮质癌的最佳方案：96例连续病例的结果
Br J Cancer. 1994 May;69(5):947-51. doi: 10.1038/bjc.1994.183.
Zotero 插件